RealPennies

Nutra Pharma Corp under the ticker symbol NPHC. Here is some more information that we have about Nutra Pharma Corp

Get our alerts and future stock picks in your email inbox


What you feel with this company ? Are you willing to
10
0
0
Nutra Pharma Corp
Nutra Pharma Corporation operates as a biotechnology company specializing in the acquisition, licensing, and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune, and infectious diseases. The company, through its subsidiaries, carries out basic drug discovery research and clinical development, and also seeks strategic licensing partnerships to reduce the risks associated with the drug development process. Nutra Pharma Corporation, through its subsidiary, ReceptoPharm, engages in the development of Cobroxin, Nyloxin OTC, and Nyloxin Rx for the treatment of moderate to severe chronic pain; RPI-78M for the treatment of neurological diseases, including Multiple Sclerosis, Adrenomyeloneuropathy, Amyotrophic Lateral Sclerosis, and Myasthenia Gravis; and RPI-MN for the treatment of viral diseases comprising HIV/AIDS and herpes. ReceptoPharm also provides contract research services through its ISO class 5 and good manufacturing practice certified facilities to third-party biotechnology and pharmaceutical companies. In addition, the company, through its other subsidiary, Designer Diagnostics, involves in the research, development, and sale of diagnostic test kits used for the rapid identification of infectious diseases, such as Nontuberculous Mycobacteria. Nutra Pharma Corporation continues to identify intellectual property and companies in the biotechnology arena. The company was founded in 2000 and is based in Coral Springs, Florida.
3 Employees
Last Reported Date: 03/31/14
Founded in 2000
Last $0.0071 USD
Change Today 0.0001 / 1.43%
Volume 11.0K
As of 5:20 PM 11/24/14 All times are local (Market data is delayed by at least 15 minutes).

nutra pharma corp (NPHC) Snapshot

Open
$0.0073
Previous Close
$0.0070
Day High
$0.0073
Day Low
$0.0071
52 Week High
06/23/14 - $0.02
52 Week Low
05/9/14 - $0.0030
Market Cap
9.9M
Average Volume 10 Days
1.1M
EPS TTM
$-0.0015
Shares Outstanding
1.4B
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Request Investor Kit
NPHC:US Advanced Stock Chart

Related News

No related news articles were found.

nutra pharma corp (NPHC) Related News

No Related News Found

nutra pharma corp (NPHC) Key Developments

Nutra Pharma Announces Completion of Commercials by MyNyloxin.com

Nutra Pharma Corp. announced that MyNyloxin.com has the exclusive rights to market and distribute Nutra Pharma's over-the-counter (OTC) pain reliever, Nyloxin(R), in the Network Marketing channel, has completed their work on a series of commercials to start airing in the month of June 2014. The advertisements focus on the benefits of Nyloxin(R) and include 30 second, 60 second and 120 second spots.

Nutra Pharma Corporation announced delayed 10-Q filing

On 05/16/2014, Nutra Pharma Corporation announced that they will be unable to file their next 10-Q by the deadline required by the SEC.

Nutra Pharma Finalizes Exclusive Network Marketing Distribution Agreement for Nyloxin

Nutra Pharma Corp. is announcing that MyNyloxin will have the exclusive rights to market and distribute Nutra Pharma's over-the-counter (OTC) pain reliever, Nyloxin(R), in the Network Marketing channel. Nutra Pharma will continue to market the products through their retail and Direct Response distributors. In September 2012, Nutra Pharma announced the beginning of distribution efforts by the TCN group of direct distributors. Since that time, TCN has worked diligently to introduce Nyloxin(R) to approximately 40,000 distributors in the United States and almost 400,000 distributors globally. TCN has now created a stand-alone opportunity for distributors under the name MyNyloxin. The launch will take place throughout the month of December and will include webinars, internet, radio and television advertising.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NPHC:US $0.01 USD 0.0001

NPHC Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Amgen Inc $164.18 USD +1.37
Bayer AG €118.06 EUR +0.89
Biogen Idec Inc $306.74 USD +3.19
Roche Holding AG SFr.288.30 CHF -1.60
 

Industry Analysis

NPHC

Industry Average

Valuation NPHC Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 19.4x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 19.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Nutra Pharma Announces the Launch of MyNyloxin.com for Nyloxin Sales Through Their Network Marketing Distributors
[Marketwired] - Nutra Pharma Corp. , a biotechnology company that is developing treatments for Adrenomyeloneuropathy , HIV and Multiple Sclerosis , is announcing that MyNyloxin, a new Network Marketing company that has ...
  Read More...
Nutra Pharma Finalizes Exclusive Network Marketing Distribution Agreement for Nyloxin
[Marketwired] - Nutra Pharma Corp. , a biotechnology company that is developing treatments for Adrenomyeloneuropathy , HIV and Multiple Sclerosis , is announcing that MyNyloxin, a new Network Marketing company, will have ...
  Read More...
10-Q for Nutra Pharma Corp.
  Read More...
NUTRA PHARMA CORP Files SEC form 10-Q, Quarterly Report
  Read More...
Nutra Pharma Announces Laboratory Recertification and Manufacturing Updates
[Marketwired] - Nutra Pharma Corp. , a biotechnology company that is developing treatments for Adrenomyeloneuropathy , HIV and Multiple Sclerosis , is announcing the recertification of their Plantation, Florida laboratory ...
  Read More...
NUTRA PHARMA CORP Financials
  Read More...
Nutra Pharma Retains BUYINS.NET to Surveil Short Sellers and Market-Makers
[Marketwired] - Nutra Pharma Corp
  Read More...
Nutra Pharma Provides Nyloxin(R) Marketing Updates
[Marketwired] - Nutra Pharma Corp. , a biotechnology company that is developing treatments for Adrenomyeloneuropathy , HIV and Multiple Sclerosis , is announcing updates to the marketing plan for their over-the-counter ...
  Read More...
NUTRA PHARMA CORP Files SEC form 10-Q/A, Quarterly Report
  Read More...
Nutra Pharma Announces Nyloxin Television Commercial Rollout
[Marketwired] - Nutra Pharma Corp. , a biotechnology company that is developing treatments for Adrenomyeloneuropathy , HIV and Multiple Sclerosis , is announcing that MyNyloxin.com, a company that has the exclusive rights ...
  Read More...
Nutra Pharma Announces Completion of Commercials by MyNyloxin.com
[Marketwired] - Nutra Pharma Corp. , a biotechnology company that is developing treatments for Adrenomyeloneuropathy , HIV and Multiple Sclerosis , is announcing that MyNyloxin.com, a new company that has the exclusive ...
  Read More...
Nutra Pharma Announces Contracts for Nyloxin Television Commercials
[Marketwired] - Nutra Pharma Corp. , a biotechnology company that is developing treatments for Adrenomyeloneuropathy , HIV and Multiple Sclerosis , is announcing that MyNyloxin.com, a new company that has the exclusive ...
  Read More...
Nutra Pharma to Seek GSA Certification, Will Market Military Strength Nyloxin to Governmental Agencies and the DoD
[Marketwired] - Nutra Pharma Corp. , a biotechnology company that is developing treatments for Adrenomyeloneuropathy , HIV and Multiple Sclerosis , is announcing that they are seeking GSA Certification in order to supply ...
  Read More...
Nutra Pharma Announces New Telemarketing and Social Media Campaign Through MyNyloxin.com
[Marketwired] - Nutra Pharma Corp. , a biotechnology company that is developing treatments for Adrenomyeloneuropathy , HIV and Multiple Sclerosis , is announcing that MyNyloxin.com, a new company that has the exclusive ...
  Read More...
NUTRA PHARMA CORP Files SEC form 10-K, Annual Report
  Read More...
Nutra Pharma Announces the First Shipments and Product Delivery to MyNyloxin.com Independent Entrepreneurs
[Marketwired] - Nutra Pharma Corp. , a biotechnology company that is developing treatments for Adrenomyeloneuropathy , HIV and Multiple Sclerosis , is announcing that they have begun shipping the initial product orders ...
  Read More...